GeoVax Labs Inc.
1256 Briarcliff Road
Atlanta
Georgia
30306
United States
Tel: 404-727-0971
Fax: 404-712-9357
Website: http://www.geovax.com/
275 articles about GeoVax Labs Inc.
-
GeoVax Announces Multiple Patent Issuances and Allowances
2/13/2024
GeoVax Labs, Inc. announced multiple actions by global patent offices strengthening the Company’s intellectual property assets.
-
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
1/4/2024
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the closure of patient enrollment for the Phase 1/2 clinical study evaluating Gedeptin® in patients suffering from advanced head and neck cancer.
-
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
11/14/2023
GeoVax Labs, Inc. announced the presentation of preclinical vaccine efficacy data for GEO-CM02, a multi-antigen investigational SARS-CoV-2 vaccine.
-
GeoVax to Participate in Upcoming November 2023 Investor and Industry Events
10/25/2023
GeoVax Labs, Inc. announced that members of its senior management team and other scientific representatives will participate in four upcoming investor and industry events during November.
-
GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities
10/24/2023
GeoVax Labs, Inc., a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced an update on key strategic initiatives.
-
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
5/24/2023
GeoVax Labs, Inc. (Nasdaq: GOVX) announced today the presentation of updates on the development of its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, including preliminary data from an ongoing Phase 2 clinical trial, during the Vaccines Summit Boston 2023 and the Congress for the International Society for the Advancement of Cytometry (CYTO) 2023 meetings.
-
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
5/9/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ Virtual Healthcare Conference being held May 23-24, 2023.
-
GeoVax to Participate in the 4th Symposium on Infectious Diseases in the Immunocompromised Host
4/26/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against cancers and infectious diseases, today announced its participation in and sponsor support of the 4th Symposium on Infectious Diseases in the Immunocompromised Host, being held April 30 to May 2, 2023, in Seattle, Washington and hosted by the Fred Hutchinson Cancer Center.
-
GeoVax to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4, 2023
4/25/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, announced today that it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the market closes.
-
GeoVax Congratulates Don Diamond, Ph.D. as Finalist for Vaccine Industry Excellence Award at World Vaccine Congress
3/15/2023
GeoVax Labs, Inc. congratulates its colleague and collaborator, Don Diamond, Ph.D. for recognition as a finalist for the Best Academic/Research Team Award, part of the Vaccine Industry Excellence Awards to be held during the World Vaccine Congress in Washington, DC on April 3-6, 2023.
-
GeoVax and EmVenio Announce Collaboration to Expand Phase 2 COVID-19 Booster Vaccine Clinical Trial
2/15/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), and EmVenio Research today announced a collaboration to deploy a mobile clinical facility in the Claremont, California area to expand GeoVax’s ongoing Phase 2 clinical trial evaluating GEO-CM04S1 as a COVID-19 booster vaccine in healthy patients.
-
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
2/7/2023
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today its clinical trial of Gedeptin® for patients with recurrent head and neck cancers is now actively enrolling patients at three major research centers -- Stanford University, Emory University and Thomas Jefferson University.
-
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2023
1/4/2023
GeoVax Labs, Inc. announced today that it will present at the Biotech Showcase coinciding with the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, January 9-12, 2023.
-
GeoVax to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 9, 2022
10/26/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines for cancer and infectious diseases, announced today that it will report third quarter 2022 financial results after the market close on Wednesday, November 9, 2022.
-
GeoVax to Present at Upcoming October 2022 Investor Conferences
10/6/2022
GeoVax Labs, Inc. announced that its Chairman & CEO, David Dodd, will present at the Midcap Rodeo: Windy City Roundup 2022 in Chicago, IL and at the LD Micro Main Event XV in Los Angeles, CA.
-
GeoVax to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/7/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 2:30 p.m. Eastern Standard Time.
-
GeoVax Announces Addition to Its Board of Directors
9/1/2022
GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced that it has appointed Nicole Lemerond, CFA, to its Board of Directors.
-
After more than two decades of attempts to develop a universal influenza vaccine, the global COVID-19 pandemic intensified the need for a broader vaccine for both illnesses.
-
GeoVax to Report Second Quarter 2022 Financial Results on Wednesday, August 3, 2022 and Provide Corporate Update
7/26/2022
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against infectious diseases and cancer, announces today that it will report second quarter 2022 financial results on Wednesday, August 3, 2022 after the market closes.
-
Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.